meglumine and optimark

meglumine has been researched along with optimark in 13 studies

Research

Studies (13)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (38.46)	29.6817
2010's	8 (61.54)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balzer, T; Hirt, U; Löwe, A	1
Barboriak, DP; Dale, BM; Merkle, EM	1
Broome, DR; Kanal, E; Martin, DR; Thomsen, HS	1
Endo, K; Takahashi-Taketomi, A; Tsushima, Y	1
Haylor, J; Morcos, SK; Vickers, ME	1
Ha, DH; Lee, SJ; Lee, SM	1
Burden, AD; Edward, M; Jardine, AG; Newton, BB; Quinn, JA	1
Abu Alfa, AK; Bauer, K; Belknap, SM; Bhatt, K; Bull, C; Cowper, SE; Edwards, BJ; Fisher, MJ; Hammel, JA; Kanal, E; Laumann, AE; McKoy, JM; Miller, FH; Nardone, B; Raisch, DW; Restaino, J; Saddleton, E; Samaras, AT; Thomsen, HS; West, DP	1
Kay, J; Todd, DJ	1
AlObaidy, M; Burke, LM; Jay, M; Ramalho, J; Ramalho, M; Semelka, RC; Vakharia, A	1
Jay, M; Prybylski, JP; Semelka, RC	1
Runge, VM	1
Al Saleh, T; Baalbaki, M; Chehabeddine, L; Hannoun, S; Khoury, SJ; Saleh, E	1

Reviews

2 review(s) available for meglumine and optimark

Article	Year
Gadolinium-Induced Fibrosis. Annual review of medicine, 2016, Volume: 67 Topics: Animals; Contrast Media; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Terminology as Topic	2016
Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommend Investigative radiology, 2017, Volume: 52, Issue:6 Topics: Animals; Bone and Bones; Brain; Contrast Media; Europe; Gadolinium; Gadolinium DTPA; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Marketing; Meglumine; Muscle, Skeletal; Organometallic Compounds; Pharmacovigilance; Practice Guidelines as Topic; Risk Assessment	2017

Article

Year

Gadolinium-Induced Fibrosis.

Annual review of medicine, 2016, Volume: 67

Topics: Animals; Contrast Media; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Terminology as Topic

2016

Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommend

Investigative radiology, 2017, Volume: 52, Issue:6

Topics: Animals; Bone and Bones; Brain; Contrast Media; Europe; Gadolinium; Gadolinium DTPA; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Marketing; Meglumine; Muscle, Skeletal; Organometallic Compounds; Pharmacovigilance; Practice Guidelines as Topic; Risk Assessment

2017

Other Studies

11 other study(ies) available for meglumine and optimark

Article	Year
Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. Investigative radiology, 2005, Volume: 40, Issue:8 Topics: Adult; Calcium; Colorimetry; Contrast Media; Diagnostic Errors; False Positive Reactions; Female; Gadolinium DTPA; Humans; Hypocalcemia; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds	2005
Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: prediction with a computer model. Academic radiology, 2007, Volume: 14, Issue:7 Topics: Abdomen; Adult; Computer Simulation; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Image Enhancement; Magnetic Resonance Angiography; Magnetics; Male; Meglumine; Middle Aged; Models, Biological; Organometallic Compounds; Predictive Value of Tests; Signal Processing, Computer-Assisted	2007
Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology, 2008, Volume: 246, Issue:1 Topics: Contrast Media; Fibrosis; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds; Renal Insufficiency; Risk; United States; United States Food and Drug Administration	2008
Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible. Radiology, 2008, Volume: 247, Issue:3 Topics: Contrast Media; Fibrosis; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds; Renal Insufficiency; Risk; Risk Factors	2008
Interference of gadolinium-based contrast agents with the measurement of serum creatinine by the Jaffe reaction. The British journal of radiology, 2009, Volume: 82, Issue:977 Topics: Animals; Contrast Media; Creatinine; Gadolinium DTPA; Humans; Kinetics; Meglumine; Organometallic Compounds	2009
Unusual variation of the rotator interval: insertional abnormality of the pectoralis minor tendon and absence of the coracohumeral ligament. Skeletal radiology, 2010, Volume: 39, Issue:12 Topics: Adolescent; Adult; Aged; Contrast Media; Female; Humans; Humerus; Ligaments, Articular; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds; Pectoralis Muscles; Retrospective Studies; Rotator Cuff; Triiodobenzoic Acids	2010
Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology, 2010, Volume: 256, Issue:3 Topics: Adult; Cell Proliferation; Collagen; Contrast Media; Dose-Response Relationship, Drug; Edetic Acid; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Hyaluronic Acid; Linear Models; Magnetic Resonance Imaging; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds	2010
Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. The British journal of radiology, 2014, Volume: 87, Issue:1042 Topics: Contrast Media; Cooperative Behavior; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Male; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Pharmacovigilance; Registries; United States	2014
Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magnetic resonance imaging, 2016, Volume: 34, Issue:10 Topics: Adult; Aged; Contrast Media; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds; Pain; Prospective Studies	2016
The stability of gadolinium-based contrast agents in human serum: A reanalysis of literature data and association with clinical outcomes. Magnetic resonance imaging, 2017, Volume: 38 Topics: Chelating Agents; Chromatography, High Pressure Liquid; Contrast Media; Data Interpretation, Statistical; Drug Stability; Gadolinium; Gadolinium DTPA; Humans; Kinetics; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds; Treatment Outcome	2017
Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents. Critical reviews in toxicology, 2019, Volume: 49, Issue:3 Topics: Adult; Brain; Cerebellar Nuclei; Contrast Media; Environmental Exposure; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Meglumine; Organometallic Compounds	2019